Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
8.80
+0.27 (3.17%)
At close: May 2, 2025, 4:00 PM
8.29
-0.51 (-5.80%)
Pre-market: May 5, 2025, 7:08 AM EDT
Ocular Therapeutix Revenue
In the year 2024, Ocular Therapeutix had annual revenue of $63.72M with 9.03% growth. Ocular Therapeutix had revenue of $17.08M in the quarter ending December 31, 2024, with 15.41% growth.
Revenue (ttm)
$63.72M
Revenue Growth
+9.03%
P/S Ratio
21.86
Revenue / Employee
$232,566
Employees
274
Market Cap
1.40B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 63.72M | 5.28M | 9.03% |
Dec 31, 2023 | 58.44M | 6.95M | 13.49% |
Dec 31, 2022 | 51.49M | 7.97M | 18.32% |
Dec 31, 2021 | 43.52M | 26.12M | 150.08% |
Dec 31, 2020 | 17.40M | 13.18M | 311.71% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
OCUL News
- 23 days ago - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Ocular Therapeutix™ to Participate in Two Investor Conferences in April - GlobeNewsWire
- 7 weeks ago - Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside - Benzinga
- 2 months ago - Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential - Seeking Alpha
- 2 months ago - Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025 - GlobeNewsWire
- 3 months ago - Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting - GlobeNewsWire
- 3 months ago - Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR - GlobeNewsWire